# US 2026/0060945 A1 · Room stable hydroxyurea oral suspension

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0060945 A1
- Document ID: US20260060945A1
- Status: Published application
- Kind: A1
- Application number: 19/104,167
- Filed: 2024-02-27
- Published: 2026-03-05
- Earliest claimed: 2023-09-20
- Assignees: Akums Drugs & Pharmaceuticals Limited
- Applicants: Akums Drugs & Pharmaceuticals Limited
- Inventors: Sanjeev JAIN; Sunil JAISWAL; Arun CHAUDHARY; Krishna PAL
- Web page: https://patentgrep.com/patent/US20260060945A1

## CPC

- A61K 31/17: having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine (isoureas, isothioureas A61K31/155; sulfonylureas A61K31/64)
- A61P 35/02: specific for leukemia
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/10: Dispersions; Emulsions
- A61K 47/02: Inorganic compounds
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a liquid composition comprising effective amount of Hydroxyurea for oral administration. The invention further discloses liquid formulation in form of ready to use oral suspension which remains stable at room temperature at the time of dispensing, storage and even after reopening of the container comprising the suspension. Also provided is a method of preparing the formulation and treating sickle cell anemia in pediatric patients.

## Claims

### Claim 1

A stable liquid formulation comprising hydroxyurea or pharmaceutically acceptable salts thereof and at least one pharmaceutically acceptable excipient wherein liquid pharmaceutical formulation is stable when stored at room temperature for longer than 3 months.

### Claim 2 (depends on 1)

The stable liquid formulation as claimed in claim 1, wherein the stable liquid formulation is ready to use oral liquid suspension.

### Claim 3 (depends on 1)

The stable liquid formulation as claimed in claim 1, comprises Hydroxyurea in an amount 5 to 15% (w/v) based on total volume of the suspension.

### Claim 4 (depends on 1)

The stable liquid formulation as claimed in claim 1, comprises Hydroxyurea in micronized form.

### Claim 5 (depends on 1)

The stable liquid formulation as claimed in claim 1, comprises at least one excipient selected from wetting agent, a suspending agent, a co-solvent, a sweetener, a flavouring agent, wetting agent, and antioxidants.

### Claim 6 (depends on 1)

A ready to use oral suspension as claimed in claim 1, comprising:
a. 5 to 15% w/v Hydroxyurea or pharmaceutically acceptable salts thereof as active ingredient and;
b. 0.05-2% w/v as sweetening agent and;
c. 0.05 to 1% w/v flavouring agent and;
d. 0.05 to 1% w/v as wetting agent and;
e. 0.005 to 0.5% w/v as antioxidant and;
f. 1 to 5% w/v as dispersing/suspending agent;
wherein the suspension is obtained by dispersing active agent with other excipients in an oily vehicle most preferably a vegetable oil.

### Claim 7 (depends on 5)

A ready to use oral suspension as claimed in claim 5, comprises:
a. 10% w/v Hydroxyurea or pharmaceutically acceptable salts thereof as active ingredient and;
b. 0.2% w/v Sucralose as sweetening agent and;
c. 0.26% w/v as strawberry dry as flavouring agent and;
d. 0.5% v/v as strawberry as flavouring agent and;
e. 0.32% w/v as Vanilla dry as flavouring agent and;
f. 0.1% w/v as Polysorbate as wetting agent/surfactant and;
g. 0.05% w/v as Vitamin E acetate as antioxidant/stabilizing agent and;
h. 1.5% w/v as Colloidal silicon dioxide as dispersing/suspending agent.

### Claim 8

A process of preparing a stable liquid formulation of Hydroxyurea wherein the process comprises the steps of:
a) preparing the bulk suspension phase by mixing vegetable oil (medium chain triglyceride) with polysorbate, colloidal silicon dioxide, sucralose and vitamin E acetate with continuous stirring for 1 hour to obtain lumpsfree suspension;
b) adding micronized Hydroxyurea with continuous stirring into bulk suspension obtain from step (a) to form a lumpsfree dispersion and allow the mixing for 01-02 hours;
c) adding flavouring agent to above solution obtained in step (b) with continuous stirring until lumpsfree dispersion obtained; and
d) filtering the suspension through a suitable filter followed by filling and sealing in a suitable packaging.
